Now accepting nominations for the FiercePharma Marketing Awards
Applications are due Friday, September 13th. Submit your nominations today.
With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.
JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.
The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.
And the winner is Publicis Groupe. Novartis has selected the agency to handle its global media account under a newly created group, NovartisONE2.
Amarin may still be waiting for the FDA to include new risk-reduction info to Vascepa's label, but in the meantime, it's getting prepared.
Roche’s targeted cancer drug Rozlytrek is officially cleared for a U.S. launch—and in not one, but two indications.
Consumers love to hate Reckitt Benckiser's Mr. Mucus, according to a new study.
More than one-fourth of all top-10 pharma TV spending in July came from one brand—AbbVie's Humira.
Consultancy ZS recently launched an editorial series called "AI &" to dive into artificial intelligence best practices for pharma.
In December, J&J touted head-to-head results for Tremfya against Novartis’ Cosentyx. But now, Lilly has topped Tremfya in a contest of its own.